Post-Treatment Surveillance to Detect Recurrent Disease in Esophagogastric Cancer: A Review of Current Practice and Future Perspectives
Open Access
- 23 September 2026
- journal article
- review article
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 15 (19) , 7389
Abstract
Effective post-treatment surveillance in cancer is designed to drive early detection and treatment of recurrence; however, surveillance protocols following curative-intent treatment for esophagogastric adenocarcinoma (EGA) remain poorly defined, with no consensus across existing guidelines. Historically, a lack of evidence regarding optimal surveillance approaches has been underpinned by limited treatment efficacy in recurrent or metastatic disease. However, recent advances in chemotherapy, immunotherapy, and targeted approaches, as well as the management of oligometastatic disease, have transformed the therapeutic landscape, making early detection of recurrence increasingly actionable. The rising incidence of EGA in younger patients adds further urgency to understanding long-term surveillance and survivorship needs. While ongoing clinical trials seek to address this question, emerging technologies, including liquid biopsy, next-generation sequencing (NGS), and artificial intelligence (AI), promise to further advance surveillance strategies. This review explores the rationale for post-treatment surveillance in EGA and examines future technologies that will shape surveillance strategies into the future.Keywords
This publication has 53 references indexed in Scilit:
- Japanese gastric cancer treatment guidelines 2025 (7th edition)Gastric Cancer, 2026
- Global prevalence of claudin 18 isoform 2 in tumors of patients with locally advanced unresectable or metastatic gastric or gastroesophageal junction adenocarcinomaGastric Cancer, 2024
- Bemarituzumab as first-line treatment for locally advanced or metastatic gastric/gastroesophageal junction adenocarcinoma: final analysis of the randomized phase 2 FIGHT trialGastric Cancer, 2024
- Nationwide survey of the follow-up practices for patients with esophageal carcinoma after radical treatment: historical changes and future perspectives in JapanEsophagus, 2021
- Efficacy and Safety of Pembrolizumab or Pembrolizumab Plus Chemotherapy vs Chemotherapy Alone for Patients With First-line, Advanced Gastric CancerJAMA Oncology, 2020
- Circulating Tumor DNA Analyses as Markers of Recurrence Risk and Benefit of Adjuvant Therapy for Stage III Colon CancerJAMA Oncology, 2019
- Effect of More vs Less Frequent Follow-up Testing on Overall and Colorectal Cancer–Specific Mortality in Patients With Stage II or III Colorectal CancerJAMA, 2018
- Safety and Efficacy of Pembrolizumab Monotherapy in Patients With Previously Treated Advanced Gastric and Gastroesophageal Junction CancerJAMA Oncology, 2018
- Effect of 3 to 5 Years of Scheduled CEA and CT Follow-up to Detect Recurrence of Colorectal CancerJAMA, 2014
- Age-Specific Trends in Incidence of Noncardia Gastric Cancer in US AdultsJAMA, 2010